The data shown in the present study from a series of stage II and III breast cancer patients treated with an anthracycline and taxan backbone schema plus antiHER in patients with Her2-positive tumors shows a clinically meaningfully difference compared to that published previously when CMF was the standard with no distinction according to HER2 status [31]. This evidence concerns the gene ERBB2 and breast cancer.